Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT
Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Investor Presentation (September 2026)
30 slides from Sagimet Biosciences Inc. - Series A's investor presentation, September 2026
Slide 1: Targeting Metabolic Dysfunction with Novel Therapeutics
Targeting Metabolic Dysfunction with Novel Therapeutics September 2026
Slide 2: Forward-Looking Statements and Disclaimer
Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of histori
Slide 3: Leadership Team with Proven Development and Commercialization Experience
Leadership Team with Proven Development and Commercialization Experience Dave Happel President & CEO Elizabeth Rozek Chief Legal & Administrative Officer >20 years of experience in executive leadership in biotech >20 years of legal experience including executive leadership and pharma of legal, IP an
Slide 4: Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation
Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation • Our lead molecule, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a differentiated Unique MOA: FASN Inhibition method of action with the potential to target multiple underserved diseases • Strong cli
Slide 5: Strong IP, Cash Position, and Collaboration Potential
Strong IP, Cash Position, and Collaboration Potential • Successful outcome of Phase 2b clinical trial in MASH (metabolic dysfunction-associated steatohepatitis); met both primary endpoints with significant reduction in fibrosis Denifanstat in Other • Pre-clinical data demonstrated synergistic effect
Slide 6: Development Pipeline: Multiple Indications and Clinical Milestones
Development Pipeline: Multiple Indications and Clinical Milestones Therapeutic Stage of Development Area Indication Milestone / Program Updates Preclinical Phase 1 Phase 2 Phase 3 Phase 3 clinical trial for the US expected to initiate in Denifanstat 2H 2026 Phase 1 FIH clinical trial initiated in Ju
Slide 7: FASN Inhibition Offers Differentiated MOA in Acne
FASN Inhibition Offers Differentiated MOA in Acne
Slide 8: Acne Market Overview
Acne Market Overview Global acne market is expected to reach $20B by 20341 Blackheads Whiteheads Papules & Pustules Cysts & Nodules 50 million people suffer with acne in the US annually2 • Acne is one of the most common skin conditions in the United States, with approximately 50 million Americans af
Slide 9: Acne Treatment Algorithm
Acne Treatment Algorithm Disease management involves flare and prevention intervention Routine Mild Disease Moderate to Severe Disease Severe (Cystic) Disease Management Treatment includes topical Treatment approach adds oral Severe (cystic) patients are Skin care routines to agents used as mono or
Slide 10: Potential Role of FASN Inhibitors in the Pathogenesis of Acne
Potential Role of FASN Inhibitors in the Pathogenesis of Acne FASN 4 key drivers of acne1: • Increased sebum in sebaceous glands (80% of lipids produced through DNL)2 Palmitate / sapienic acid • Abnormal or excessive follicular hyper-keratinization • Accelerated bacterial growth (C. acnes) Lipid syn
Slide 11: Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne
Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne In multiple Phase 1 clinical trials, denifanstat Phase 1 oncology clinical trial demonstrated a decrease in DNL sebum lipids1-3 Sebutape® assessment of cutaneous sebum lipids1,2 • Demonstrated a >90% reduction in sebum lipids by
Slide 12: Denifanstat's Clinical Data in Acne
Denifanstat’s Clinical Data in Acne
Slide 13: Design of Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304)
Design of Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304) Clinical Trials Conducted in China by Sagimet’s License Partner, Ascletis Phase 3 Phase 3 Denifanstat Phase 3 in Acne Double blind clinical trial1 Open label extension (OLE)2 ASC40-303 ASC40-304 Denifanstat (50mg) • Moderate to severe
Slide 14: ASC40-303 Baseline Characteristics
ASC40-303 Baseline Characteristics Baseline Characteristics 50mg denifanstat Placebo Total (n=240) (n=240) (n=480) Age, years, mean (SD) 22.7 (4.0) 22.5 (3.5) 22.6 (3.8) Male, n (%) 79 (32.9) 71 (29.6) 150 (31.3) Female, n (%) 161 (67.1) 169 (70.4) 330 (68.8) IGA=3 (moderate), n (%) 206 (85.8) 206 (
Slide 15: Denifanstat Met All Primary and Secondary Endpoints in Acne Phase 3 Clinical Trial (ASC40-303)
Denifanstat Met All Primary and Secondary Endpoints in Acne Phase 3 Clinical Trial (ASC40-303) 50mg denifanstat Placebo 50mg denifanstat Efficacy endpoints 1 p value (n=240) (n=240) (placebo adjusted) % Treatment success (IGA) 2 (primary endpoint) 33.2 14.6 18.6 <0.0001 % Change in total lesion coun
Slide 16: In ASC40-303, Denifanstat Showed Statistically Significant Effect on Skin Lesions Starting Week 4
In ASC40-303, Denifanstat Showed Statistically Significant Effect on Skin Lesions Starting Week 4 Percent Change in Total, Inflammatory and Non-inflammatory Lesion Count Over Time *** ** *** ** *** *** *** *** *** Ascletis data on file. Note: * p<0.01, ** p<0.01, *** p<0.001 September 2026 16
Slide 17: ASC40-303 Safety Data
ASC40-303 Safety Data Denifanstat 50mg Was Generally Well-Tolerated During the 12-Week Clinical Trial Adverse events (AEs): • AE incidence rates were comparable between denifanstat and placebo • Only two categories of treatment related AEs had an incidence rate of 5% or more: • Dry eye (investigator
Slide 18: Baseline Characteristics of ASC40-304 Extension Cohorts at ASC40-303 Baseline
Baseline Characteristics of ASC40-304 Extension Cohorts at ASC40-303 Baseline Baseline characteristics of OLE cohorts consistent with overall study population Baseline Characteristics Denifanstat/Denifanstat Placebo/Denifanstat ASC40-303 Total Baseline (n=116) (n=124) (n=480) Age, years, mean (SD) 2
Slide 19: ASC40-304 Safety Data
ASC40-304 Safety Data Denifanstat Generally Well-Tolerated in the OLE Clinical Trial Adverse events (AEs): • All denifanstat-related AEs were mild or moderate; no denifanstat-related Grade 3 or 4 AEs • Only two categories of treatment related AEs had an incidence of 5% or more in denifanstat-treated
Slide 20: During the OLE (ASC40-304), Patients Showed Further Improvement in IGA Success
During the OLE (ASC40-304), Patients Showed Further Improvement in IGA Success Compared to ASC40-303 Baseline % Patients with IGA ≥ 3 at ASC40-303 Baseline Reaching IGA of 0 or 1 during OLE ASC40-303 ASC40-303 & 304 Ascletis data on file. Week 52/ET (“Early Termination”) = patients who completed the
Slide 21: During the OLE, Further Reduction in Inflammatory Lesion Counts
During the OLE (ASC40-304), Patients Showed Further Reduction in Inflammatory Lesion Counts (ILC) Compared to ASC40-303 Baseline ILC Mean % Change From ASC40-303 Baseline in OLE Patients ASC40-303 ASC40-303 & 304 Inflammatory skin lesion counts reduced by approximately 80% compared to ASC40-303 base
Slide 22: During the OLE, Further Reduction in Non-Inflammatory Lesion Counts
During the OLE (ASC40-304), Patients Showed Further Reduction in Non- Inflammatory Lesion Counts (NILC) Compared to ASC40-303 Baseline NILC Mean % Change From ASC-303 Baseline in OLE Patients ASC40-303 ASC40-303 & 304 Ascletis data on file. Week 52/ET (“Early Termination”) = patients who completed t
Slide 23: During the OLE, Further Reduction in Total Lesion Counts
During the OLE (ASC40-304), Patients Showed Further Reduction in Total Lesion Counts (TLC) Compared to ASC40-303 Baseline TLC Mean % Change in TLC From ASC40-303 Baseline in OLE Patients ASC40-303 ASC40-303 & 304 Total skin lesion counts reduced by approximately 75% compared to ASC40-303 baseline fo
Slide 24: Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304) Summary
Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304) Summary • In ASC40-303, patients dosed with denifanstat 50mg over 12 weeks demonstrated statistically significant improvement in: • Investigator Global Assessment (IGA)-scores • Inflammatory, non-inflammatory, and total lesion counts • In ASC40-
Slide 25: Sagimet's Development Programs
Sagimet’s Development Programs
Slide 26: AURORA Phase 3 Clinical Trial for Denifanstat in Acne
AURORA Phase 3 Clinical Trial for Denifanstat in Acne AURORA Phase 3 acne clinical trial design 12 week 40 week Double blind clinical trial Open label extension • Moderate to severe acne Denifanstat (50mg) • Multi-center placebo controlled N= 533 Denifanstat (50mg) • 2:1 randomization Screening N~53
Slide 27: FASN Inhibitor TVB-3567 FIH Ongoing Phase 1 Clinical Trial
FASN Inhibitor TVB-3567 FIH Ongoing Phase 1 Clinical Trial Initiated in June 2025 A double-blind, randomized, placebo-controlled clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of TVB-3567 in healthy participants with or
Slide 28: Potential Clinical Development Program for TVB-3567 in Acne
Potential Clinical Development Program for TVB-3567 in Acne Phase 1 clinical trial initiated in June 2025 Goal: Initiate Phase 2 clinical trial in 2026, subject to consultation with regulatory authorities and outcome of Phase 1 clinical trial • Step 1 - Phase 1 first-in-human pharmacokinetic (PK) cl
Slide 29: Denifanstat for Treatment of MASH
Denifanstat for Treatment of MASH Clinical and pre-clinical data demonstrate denifanstat’s potential to treat MASH (metabolic dysfunction- associated steatohepatitis) • MASH F2-F3: • Denifanstat met both primary endpoints in Phase 2b clinical trial, with significant reduction in fibrosis and was gen
Slide 30: FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne
FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne • Acne market is significant (~50m people in the US) and aligned to those patients most likely to be prescribed an oral FASN inhibitor FASN Inhibition in Acne • Oral FASN inhibitors offer a novel mechanism of action for the pot
Sagimet Biosciences — Investor Presentation (September 2026) on 6ix